FI822173L - Nya orala dipyridamolformer - Google Patents

Nya orala dipyridamolformer

Info

Publication number
FI822173L
FI822173L FI822173A FI822173A FI822173L FI 822173 L FI822173 L FI 822173L FI 822173 A FI822173 A FI 822173A FI 822173 A FI822173 A FI 822173A FI 822173 L FI822173 L FI 822173L
Authority
FI
Finland
Prior art keywords
dipyridamolformer
orala
nya
orala dipyridamolformer
nya orala
Prior art date
Application number
FI822173A
Other languages
English (en)
Other versions
FI80829C (fi
FI822173A0 (fi
FI80829B (fi
Inventor
Rolf Brickl
Peter Gruber
Gottfried Schepky
Gerhard Bozler
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6134913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI822173(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of FI822173A0 publication Critical patent/FI822173A0/fi
Publication of FI822173L publication Critical patent/FI822173L/fi
Application granted granted Critical
Publication of FI80829B publication Critical patent/FI80829B/fi
Publication of FI80829C publication Critical patent/FI80829C/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI822173A 1981-06-19 1982-06-17 Foerfarande foer att framstaella nya orala instatnpreparat av dipyridamol. FI80829C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3124090 1981-06-19
DE19813124090 DE3124090A1 (de) 1981-06-19 1981-06-19 Neue orale dipyridamolformen

Publications (4)

Publication Number Publication Date
FI822173A0 FI822173A0 (fi) 1982-06-17
FI822173L true FI822173L (fi) 1982-12-20
FI80829B FI80829B (fi) 1990-04-30
FI80829C FI80829C (fi) 1990-08-10

Family

ID=6134913

Family Applications (1)

Application Number Title Priority Date Filing Date
FI822173A FI80829C (fi) 1981-06-19 1982-06-17 Foerfarande foer att framstaella nya orala instatnpreparat av dipyridamol.

Country Status (27)

Country Link
US (1) US4427648A (fi)
EP (1) EP0068191B2 (fi)
JP (1) JPS5849312A (fi)
KR (1) KR880001090B1 (fi)
AR (1) AR228779A1 (fi)
AT (1) ATE17317T1 (fi)
AU (1) AU555951B2 (fi)
CA (1) CA1200496A (fi)
DD (1) DD202505A5 (fi)
DE (2) DE3124090A1 (fi)
DK (1) DK158540C (fi)
ES (1) ES8304797A1 (fi)
FI (1) FI80829C (fi)
GB (1) GB2101484B (fi)
GR (1) GR76503B (fi)
HU (1) HU186078B (fi)
IE (1) IE53543B1 (fi)
IL (1) IL66075A (fi)
IN (1) IN158513B (fi)
MA (1) MA19503A1 (fi)
MX (1) MX160712A (fi)
MY (1) MY8700727A (fi)
NZ (1) NZ201008A (fi)
PH (1) PH25637A (fi)
PT (1) PT75077B (fi)
SU (1) SU1151193A3 (fi)
ZA (1) ZA824315B (fi)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
ATE120089T1 (de) * 1991-05-20 1995-04-15 Marion Laboratories Inc Mehrschichtige zubereitung mit kontrollierter freisetzung.
US5302393A (en) * 1991-07-11 1994-04-12 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
DE19845358A1 (de) 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
EP2062580A1 (en) 2003-04-24 2009-05-27 Boehringer Ingelheim International GmbH Use of dipyridamole or mopidamole for treatment and prevention of thromboembolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of trombin receptors
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
CA2566081A1 (en) * 2004-05-13 2005-12-01 Boehringer Ingelheim International Gmbh Use of dipyridamole for treatment of resistance to platelet inhibitors
BG860Y1 (bg) * 2004-09-17 2007-02-28 "Софарма" Ад Лекарствена форма на дипиридамол
PT2559430E (pt) 2005-03-22 2015-10-09 Stada Arzneimittel Ag Ibuprofeno solubilizado
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
AU2006284053B2 (en) * 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
ES2531215T3 (es) * 2006-01-27 2015-03-11 Aptalis Pharmatech Inc Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos
NZ569984A (en) * 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
WO2007092026A1 (en) * 2006-02-09 2007-08-16 Teva Pharmaceutical Industries Ltd. Dipyridamole extended-release formulations and process for preparing same
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
MX2010007207A (es) 2007-12-28 2011-02-23 Impax Laboratories Inc Formulaciones de liberacion controlada de levodopa y usos de las mismas.
US20090196935A1 (en) * 2008-02-01 2009-08-06 Ahmed Salah U Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20100080846A1 (en) * 2008-09-25 2010-04-01 Avshalom Ben-Menachem Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
WO2011014741A1 (en) * 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
JP2014517843A (ja) * 2011-05-24 2014-07-24 テバ ファーマシューティカル インダストリーズ リミティド 医薬組成物用の圧縮コア
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
AU2014332024B2 (en) 2013-10-07 2019-09-26 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2014359427B2 (en) 2013-12-04 2017-04-20 Boehringer Ingelheim Vetmedica Gmbh Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2157201C3 (de) * 1970-11-13 1974-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verbesserte feste orale Applikationsform von Raubasin
DE2700433A1 (de) * 1977-01-07 1978-07-20 Kali Chemie Pharma Gmbh Arzneimittelzubereitungen mit verbesserten resorptionseigenschaften
LU77353A1 (fi) * 1977-05-16 1979-01-19
DD146547A5 (de) 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS6116368A (ja) * 1984-07-02 1986-01-24 Mitsubishi Electric Corp 画像処理装置の検査装置

Also Published As

Publication number Publication date
JPH0251402B2 (fi) 1990-11-07
IL66075A (en) 1985-09-29
HU186078B (en) 1985-05-28
DK158540C (da) 1990-11-12
DE3124090A1 (de) 1983-01-05
FI80829C (fi) 1990-08-10
AU555951B2 (en) 1986-10-16
US4427648A (en) 1984-01-24
DE3124090C2 (fi) 1991-11-21
PT75077B (de) 1985-05-31
AU8496582A (en) 1982-12-23
IL66075A0 (en) 1982-09-30
IE53543B1 (en) 1988-12-07
DE3268380D1 (en) 1986-02-20
PH25637A (en) 1991-08-21
MX160712A (es) 1990-04-23
EP0068191A3 (en) 1983-08-10
IN158513B (fi) 1986-11-29
ZA824315B (en) 1984-02-29
PT75077A (de) 1982-07-01
FI822173A0 (fi) 1982-06-17
IE821453L (en) 1982-12-19
GB2101484B (en) 1984-09-19
KR880001090B1 (ko) 1988-06-23
EP0068191B1 (de) 1986-01-08
GB2101484A (en) 1983-01-19
MA19503A1 (fr) 1982-12-31
MY8700727A (en) 1987-12-31
DK269682A (da) 1982-12-20
GR76503B (fi) 1984-08-10
ATE17317T1 (de) 1986-01-15
EP0068191A2 (de) 1983-01-05
DD202505A5 (de) 1983-09-21
KR840000229A (ko) 1984-02-18
AR228779A1 (es) 1983-04-15
CA1200496A (en) 1986-02-11
NZ201008A (en) 1985-11-08
ES513235A0 (es) 1983-03-16
EP0068191B2 (de) 1991-09-11
ES8304797A1 (es) 1983-03-16
SU1151193A3 (ru) 1985-04-15
JPS5849312A (ja) 1983-03-23
DK158540B (da) 1990-06-05
FI80829B (fi) 1990-04-30

Similar Documents

Publication Publication Date Title
FI822173A0 (fi) Nya orala dipyridamolformer
FI822243L (fi) Nya n-aryl-piperazinalkanamider
FI820042L (fi) Framstaellningsfoerfarande foer nya i 11beta-staellning substituerade steroidderivat
FI822511A0 (fi) Nya bicykliska pyrimidin-5-on-derivat
FI810287L (fi) Nya antihyperkolesterolemiska foereningar
FI833859A0 (fi) Nya azolfoereningar
FI820689L (fi) Nya n-acylpolypeptider och foerfaranden foer deras framstaellning
FI811504L (fi) Nya triazolokinoxalin-4-oner
FI820509L (fi) Nya azepinderivater deras framstaellning och deras anvaendningsaosom laekemedel
FI821833A0 (fi) Foerfarande foer framstaellning av nya antracykliner
FI822785A0 (fi) Nya imidazokinazolinderivat
FI822803A0 (fi) Nya karbostyrilderivat
FI820060L (fi) Nya karboxylsyra-derivat deras framstaellning och deras anvaendning saosom laekemedel
FI832556A (fi) Nya 19-tio-androstanderivat
FI821305A0 (fi) Foerfarande foer framstaellning av nya alifatiska fenylkarboxylsyraderivat
FI813946L (fi) Nya estrar
FI801843A (fi) Nya karbostyrilderivat
FI823156L (fi) Foerfarande foer framstaellning av nya polycykliska polyazaheterocykler
FI833480A (fi) Nya antracyklinglykosider
FI822526A0 (fi) Nya bicykliska foereningar och foerfarande foer deras framstaellning
FI834481A0 (fi) Nya etenamidin- och guanidinderivat
FI822215L (fi) Foerfarande foer framstaellning av nya benzoyl-fenyl-piperdinderivat
FI831778L (fi) Nya dihydropyridiner
FI820339L (fi) Nya apovinkaminolderivat
FI813140L (fi) Nya prostaglandiner

Legal Events

Date Code Title Description
MA Patent expired

Owner name: DR. KARL THOMAE GESELLSCHAFT MIT